Skip to Content
Merck
CN

Key Documents

View All Documentation

F8257

Flunarizine dihydrochloride

≥98% (TLC), T-type Ca2+/Na+ channel blocker

Synonym(s):

1-[Bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)piperazine dihydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C26H26F2N2 · 2HCl
CAS Number:
30484-77-6
Molecular Weight:
477.42
NACRES:
NA.77
PubChem Substance ID:
24277835
UNSPSC Code:
12352200
EC Number:
250-216-6
MDL number:
MFCD00058198
Beilstein/REAXYS Number:
4284243
Assay:
≥98% (TLC)
Quality level:
200
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Flunarizine dihydrochloride, ≥98% (TLC)

Quality Level

200

assay

≥98% (TLC)

originator

Johnson & Johnson

storage temp.

2-8°C

SMILES string

Cl[H].Cl[H].Fc1ccc(cc1)C(N2CCN(CC2)C\C=C\c3ccccc3)c4ccc(F)cc4

InChI

1S/C26H26F2N2.2ClH/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21;;/h1-15,26H,16-20H2;2*1H/b7-4+;;

InChI key

RXKMOPXNWTYEHI-RDRKJGRWSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Flunarizine has antihistamine, anticonvulsant and vestibular depressive properties. It protects endothelial cells from calcium overload-induced damage. Flunarizine is used to treat epilepsy, migraine prophylaxis, cerebral blood flow disturbances, peripheral vascular disease and vertigo.

Application

Flunarizine dihydrochloride has been used to study the effect of flunarizine on epileptiform activity. It is also used to study its effect on high-potassium induced increase of intracellular free calcium.

Biochem/physiol Actions

Blocks T-type Ca2+/Na+ channels.
Blocks T-type Ca2+/Na+ channels; inhibits K+-induced catecholamine release from chromaffin cells

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000521569
0000521569
0000514925
0000514925
0000451097

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

R Aishworiya et al.
Annals of tropical paediatrics, 31(2), 149-152 (2011-05-18)
Alternating hemiplegia of childhood (AHC) is a rare neurological disorder which usually presents before 18 months of age and is characterised by recurrent alternating episodes of hemiparesis. A single effective treatment for this condition is yet to be established; flunarizine
Li Li et al.
Circulation. Arrhythmia and electrophysiology, 6(6), 1192-1199 (2013-11-19)
Previous studies showed that endocardial activation during long-duration ventricular fibrillation (VF) exhibits organized activity. We identified and quantified the different types of organized activity. Two 64-electrode basket catheters were inserted, respectively, into the left ventricle and right ventricle of dogs
Hunmin Kim et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 17(1), 45-49 (2012-11-01)
The purpose of this study was to compare the efficacy and tolerability of topiramate and flunarizine for the prophylaxis of pediatric migraines. A retrospective medical-record review of patients who underwent prophylaxis after receiving a diagnosis of migraine with aura and
Flunarizine
Holmes B, et al.
Drugs, 27(1), 6-44 (1984)
Barbara Budzynska et al.
Behavioural brain research, 228(1), 144-150 (2011-12-20)
The motivational component of drug withdrawal may contribute to drug seeking and relapse through the negative reinforcement-related process; thus, it is important to understand the mechanisms that mediate affective withdrawal behaviors. The present study was undertaken to examine the calcium-dependent
View All Related Papers

Global Trade Item Number

SKUGTIN
F8257-1G04061833620410
F8257-10G04061832961637

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service